Navigation Links
Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
Date:12/16/2008

SAN DIEGO, Dec. 16 /PRNewswire/ -- Accumetrics, Inc. has appointed 20-year industry veteran Ad de Waard as Vice President of International Sales and Marketing.

"Ad joins us at an important juncture in the evolution of Accumetrics, as we are now well-positioned to expand our international business," says Timothy I. Still, President and CEO at Accumetrics. "His extensive experience in managing global distribution networks will be invaluable as we continue on our growth path and expand our capabilities to provide Accumetrics' products to customers worldwide."

Mr. de Waard has more than 20 years' experience in the in-vitro diagnostics industry in roles of increasing responsibility involving international sales and marketing and general management. He has launched several new cardiovascular products, including products in the area of platelet function analysis.

Prior to Accumetrics, Mr. de Waard served as Director of International Business Development at Inverness, Inc., which acquired HemoSense, Inc. in 2007. Prior to his time at HemoSense, he held various international marketing positions, including those at Dade Behring and Amersham International. In his new position at Accumetrics, Mr. de Waard will be based in the Netherlands.

Mr. de Waard holds several degrees and certificates, including his HBO (the Dutch equivalent of a bachelor degree) from the School of Clinical Chemistry, The Netherlands, MBO certificates in process chemistry and electrotechnology, and completion of the marketing program at the Netherlands Institute of Marketing.

AboutAccumetrics(www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

    CONTACT:  Jules Abraham
              Lippert Heilshorn & Associates
              212-838-3777
              jabraham@lhai.com

              Timothy I. Still
              Accumetrics
              press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
2. William Moore Appointed to IRIDEX Board of Directors
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
5. James B. Hawkins Appointed to IRIDEX Board of Directors
6. Bryan R. Rogers Appointed President of Far West Division
7. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
8. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
9. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... , ... May 26, 2016 , ... In an effort to provide hair restoration information ... both Snapchat users and those who do not use the app. Dr. Mohebi, the founder ... page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... comprehensive treatment for eating disorders, is opening a brand new child and adolescent ... ages 8-17 and their families with even more specialized eating disorder treatment and ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
(Date:5/27/2016)... 2016 Kitov Pharmaceuticals ... on late-stage drug development, today announced the completion ... pivotal batches required for registration of KIT-302 with ... follows Kitov,s announcement in December 2015, ... its primary efficacy endpoint. "We are ...
Breaking Medicine Technology: